Moody National Bank Trust Division Invests $908,000 in GRAIL, Inc. $GRAL

Moody National Bank Trust Division acquired a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 13,300 shares of the company’s stock, valued at approximately $908,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GRAL. Fifth Third Bancorp lifted its stake in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after buying an additional 472 shares during the period. N.E.W. Advisory Services LLC bought a new stake in shares of GRAIL in the 4th quarter valued at about $26,000. Comerica Bank increased its stake in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of GRAIL in the 4th quarter valued at about $28,000. Finally, Geneos Wealth Management Inc. raised its position in shares of GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after acquiring an additional 360 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GRAL. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Wolfe Research assumed coverage on shares of GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Robert W. Baird set a $70.00 price target on shares of GRAIL in a research report on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group started coverage on shares of GRAIL in a research report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $67.78.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Revenue and earnings beat expectations: GRAIL reported second-quarter revenue of $44.7 million, above the $42.4 million consensus estimate, while its adjusted loss of $2.56 per share was $0.10 better than expected. GRAIL quarterly earnings report
• Positive Sentiment: Galleri commercial momentum remained strong: Second-quarter Galleri test volume increased 35% year over year to more than 61,000 tests, while Galleri revenue rose 24% to $42.6 million. For the first half, test volume grew 42% and revenue increased 30%. GRAIL Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Clinical progress and additional capital: GRAIL cited favorable NHS-Galleri and PATHFINDER 2 results presented at the 2026 ASCO meeting and completed a $110 million equity financing with Samsung. The funding strengthens liquidity for commercialization and research, although it may increase share count. GRAIL clinical results and financing announcement
• Neutral Sentiment: Profitability remains distant: Despite the revenue and EPS beats, GRAIL continues to operate at a substantial loss, with a negative net margin of 253.22% and analysts expecting a full-year loss of approximately $10.91 per share. GRAIL financial information
• Negative Sentiment: Ongoing securities litigation adds risk: Multiple law firms publicized a class-action lawsuit involving GRAIL and solicited investors to seek lead-plaintiff status. The announcements could weigh on sentiment and create potential legal costs or liabilities, although they do not represent a court finding against the company. Portnoy Law Firm class-action announcement

Insider Activity at GRAIL

In related news, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.83% of the stock is currently owned by insiders.

GRAIL Stock Performance

Shares of GRAL opened at $74.18 on Thursday. The stock has a 50 day simple moving average of $66.97 and a 200 day simple moving average of $66.72. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84. The firm has a market capitalization of $3.18 billion, a PE ratio of -7.15 and a beta of 3.24.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. Equities research analysts predict that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.